Pulmatrix, Inc. (NASDAQ:PULM) Sees Large Drop in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 4,299 shares, a drop of 25.1% from the November 30th total of 5,742 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 13,084 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily volume of 13,084 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the shares of the stock are sold short.

Institutional Trading of Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned about 0.30% of Pulmatrix at the end of the most recent reporting period. 11.84% of the stock is currently owned by institutional investors.

Pulmatrix Price Performance

PULM traded up $0.05 during trading on Wednesday, reaching $2.23. 30,628 shares of the company’s stock were exchanged, compared to its average volume of 23,449. The company’s fifty day moving average price is $4.21 and its 200-day moving average price is $5.05. Pulmatrix has a fifty-two week low of $2.15 and a fifty-two week high of $10.40.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings results on Thursday, October 16th. The biotechnology company reported ($0.24) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a research note on Monday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).